Tysabri Safety Data To Be Submitted To FDA This Fall, Biogen Idec/Elan Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan will complete a Tysabri safety review by late summer in the hopes of bringing the multiple sclerosis therapy back on the market.
You may also be interested in...
Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.
Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.
Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.
Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.
Tysabri Could Return To Market As “Niche” Drug, Analyst Says
Morgan Stanley report predicts sales of $500 mil. for Biogen Idec/Elan’s multiple sclerosis therapy if it returns to market. Analyst’s review shows additional safety signals.